Yes, oral micronized progesterone 200 mg daily can be used for postmenopausal women with a uterus on estrogen therapy, but only when given sequentially for 12-14 days per month—not as continuous daily therapy.
FDA-Approved Sequential Dosing
The FDA-approved regimen for endometrial protection is 200 mg oral micronized progesterone at bedtime for 12 consecutive days per 28-day cycle 1. This sequential approach has been validated for preventing endometrial hyperplasia in postmenopausal women receiving daily conjugated estrogens 1.
Why Sequential, Not Continuous Daily?
The critical distinction is duration and timing:
- Sequential regimen (12-14 days/month at 200 mg): Provides adequate endometrial protection for up to 5 years 2
- Continuous daily regimen: The evidence for 200 mg daily continuous use is insufficient for endometrial protection
The 2015 Endocrine Society guidelines specify that progestogens can be administered either sequentially (12-15 days each month) or continuously, but they do not provide specific dosing for continuous micronized progesterone regimens 3. The sequential approach is preferred for recently menopausal women prone to breakthrough bleeding 3.
Evidence Concerns with Continuous Regimens
A high-quality 2021 study (ELITE trial) demonstrated that vaginal progesterone 45 mg/day for only 10 days per month was insufficient to oppose oral estradiol effects, resulting in progressive endometrial thickening and higher rates of endometrial hyperplasia 4. This raises concerns about whether any intermittent dosing—even at higher doses—provides adequate protection, and suggests continuous regimens may require different dosing strategies.
Clinical Implementation
For postmenopausal women with a uterus requiring progestogen protection:
- Use 200 mg oral micronized progesterone at bedtime for days 1-12 (or 10-14) of each 28-day cycle 1, 2
- Administer with a glass of water while standing if swallowing difficulties occur 1
- Expect secretory endometrial transformation without hyperplasia 5, 6
- Anticipate potential drowsiness/dizziness; bedtime dosing mitigates this 1, 7
Important Caveats
- Peanut allergy is an absolute contraindication (formulation contains peanut oil) 1
- Sequential regimens may cause withdrawal bleeding, particularly in early menopause 3
- Continuous combined regimens using 100 mg daily micronized progesterone exist but lack robust FDA validation for the 200 mg dose 8
- Transdermal micronized progesterone does NOT provide endometrial protection 2
The evidence strongly supports sequential use of 200 mg for 12-14 days monthly, not continuous daily administration at this dose.